Digital Biotechnologies Inc., a new Seattle-based subsidiary of publicly traded immune medicine company Adaptive Biotechnologies, has raised fresh cash as part of an initial closing of a Series A inve... ...

Core Insights - Adaptive Biotechnologies Corporation is participating in the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, CA on January 12, 2026 [1][2] Company Overview - Adaptive Biotechnologies is a commercial-stage biotechnology company focused on leveraging the adaptive immune system for disease diagnosis and treatment [3] - The company aims to decode the adaptive immune system's genetics to enhance its diagnostic and therapeutic capabilities [3] - Its proprietary immune medicine platform is designed to translate the genetics of the adaptive immune system with scale, precision, and speed [3] - The company operates in two business segments: Minimal Residual Disease (MRD) and Immune Medicine, developing clinical diagnostics and partnering with biopharmaceutical companies [3] - The goal is to create immune-driven clinical products tailored to individual patients for diseases such as cancer and autoimmune disorders [3]

Adaptive Biotechnologies said on Monday it has signed two non-exclusive deals with Pfizer to support research in rheumatoid arthritis and other immune-related diseases. ...

A target discovery agreement to identify disease-specific T-cell receptors (TCRs) in rheumatoid arthritis A data licensing agreement to access Adaptive’s proprietary TCR-antigen datasets for research and development in multiple immunology applications SEATTLE, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (NASDAQ: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, tod ...

SEATTLE, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced Dr. Harlan Robins, Chief Scientific Officer and Co-Founder and Susan Bobulsky, Chief Commercial Officer, MRD will be participating in a Jefferies fireside chat to discuss Minimal Residual Disease (MRD) in Hematology/Oncology with deep dive ...

Core Viewpoint - Adaptive Biotechnologies Corp. experienced a significant decline of 24.5% in its stock price due to the sale of substantial stakes by key executives, raising concerns among investors [1][2]. Executive Sales - Chairman and CEO Chad Robins sold $3.07 million worth of shares in two transactions on November 26 and December 1, with average prices between $18.94 and $19.68 [2]. - Chief Financial Officer Kyle Piskel sold $3.17 million worth of shares on November 28, covering 162,820 shares at a price of $19.5 each, while also acquiring $1.25 million in new shares at prices ranging from $6.55 to $12.14 [2]. - Harlan Robins, the Chief Scientific Officer, disposed of $672,515 worth of shares at prices between $16.61 and $18.61 [2]. Regulatory Compliance - The transactions by the executives were conducted in accordance with the Rule 10b5-1 trading plan adopted in August [2]. Market Perception - Insider selling is generally viewed negatively by ordinary investors due to potential business concerns, although such sales can also be attributed to profit-taking and personal reasons [2]. Investment Outlook - While Adaptive Biotechnologies has potential as an investment, there is a belief that certain AI stocks may offer better returns with limited downside risk [2].

Core Insights - Adaptive Biotechnologies Corporation is showcasing the increasing interventional use of its clonoSEQ® test at the 67th American Society of Hematology Annual Meeting, with 90 abstracts featuring clonoSEQ data [1] - The clonoSEQ test is being utilized to guide clinical decisions in blood cancer treatment, particularly in assessing measurable residual disease (MRD) status [3][8] Group 1: Clinical Studies and Findings - The phase II EndRAD study supports the use of next-generation sequencing (NGS) MRD status prior to allogeneic hematopoietic cell transplantation (HCT) to select non-total body irradiation (TBI) conditioning approaches, showing excellent event-free and overall survival in 51 NGS MRD negative patients [2] - In multiple myeloma (MM), a phase III AURIGA study demonstrated that deep MRD responses correlate with improved progression-free survival, with intensified maintenance post-transplant doubling MRD negativity rates [7] - A phase II study in chronic lymphocytic leukemia (CLL) showed that a combination therapy achieved deep and durable remissions based on MRD assessment, highlighting clonoSEQ's role in guiding treatment duration [7] Group 2: Impact on Treatment Approaches - clonoSEQ MRD status is being used by healthcare providers to tailor treatment intensity and duration, enhancing precision in clinical decision-making [3][8] - The data presented at ASH indicates a shift towards using clonoSEQ to de-escalate therapy in certain patient populations, such as frail older adults with diffuse large B-cell lymphoma (DLBCL) [7] - The unprecedented volume of data at ASH reinforces clonoSEQ's leadership in blood cancer MRD monitoring, reflecting its value in therapeutic progress and patient management [8] Group 3: Product Overview - clonoSEQ is the first FDA-cleared in vitro diagnostic test for detecting and tracking MRD in patients with multiple myeloma, B-cell acute lymphoblastic leukemia, and chronic lymphocytic leukemia [9] - The test identifies and quantifies DNA sequences in malignant cells, detecting one cancer cell in one million healthy cells, which aids clinicians in monitoring MRD with precision [10] - clonoSEQ is covered by Medicare for multiple myeloma, CLL, ALL, DLBCL, and mantle cell lymphoma, indicating its established role in clinical practice [9]

Core Insights - Adaptive Biotechnologies Corporation is showcasing the increasing interventional use of its clonoSEQ test at the 67th American Society of Hematology Annual Meeting, with 90 abstracts featuring clonoSEQ data, including 17 that demonstrate its role in guiding clinical actions for blood cancer patient care [1][9] Group 1: Clinical Applications and Studies - The phase II EndRAD study supports the use of next-generation sequencing (NGS) measurable residual disease (MRD) status prior to allogeneic hematopoietic cell transplantation (HCT) to select non-total body irradiation (TBI) conditioning approaches, showing excellent event-free and overall survival in 51 NGS MRD negative patients [2][3] - Across hematologic malignancies, clonoSEQ MRD status is utilized by healthcare providers to guide clinical decisions, with presentations demonstrating its application in tailoring treatment intensity and duration [3][9] - A phase III AURIGA study involving 200 newly diagnosed multiple myeloma (MM) patients showed that deep MRD responses correlated with improved progression-free survival, and intensified maintenance in MRD-positive patients post-transplant doubled MRD negativity rates [7] Group 2: Abstracts and Research Findings - A total of 32 abstracts on multiple myeloma will be presented, focusing on MRD assessment of treatment response and real-world data linking MRD status to clinical outcomes [7] - In non-Hodgkin lymphoma (NHL), 15 abstracts will explore MRD to understand treatment response depth and guide therapy, including a study on de-escalating therapy in frail older adults with diffuse large B-cell lymphoma (DLBCL) [7] - Data from a phase II study of 80 previously untreated chronic lymphocytic leukemia (CLL) patients indicated that time-limited therapy achieved deep and durable remissions based on MRD assessment [8] Group 3: clonoSEQ Overview - clonoSEQ is the first FDA-cleared in vitro diagnostic test for detecting and tracking MRD in patients with multiple myeloma, B-cell acute lymphoblastic leukemia, and chronic lymphocytic leukemia, and is also available for other lymphoid cancers as a CLIA-validated laboratory developed test [10][11] - The test identifies and quantifies DNA sequences in malignant cells, detecting one cancer cell in one million healthy cells, providing standardized and sensitive results that inform treatment decisions and predict outcomes [11]

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) stock is trading lower on Friday, despite no company-specific news, likely reacting to Natera Inc.'s (NASDAQ:NTRA) acquisition of cancer diagnostics firm Foresight Diagnostics for $275 million upfront and up to $175 million in additional earnouts tied to revenue- and reimbursement-based milestones."This acquisition reinforces Natera's position at the forefront of precision oncology," said Steve Chapman, chief executive officer of Natera.William Blair writes ...

Summary of Adaptive Biotechnologies FY Conference Call Company Overview - **Company**: Adaptive Biotechnologies (NasdaqGS:ADPT) - **Focus**: Development of clonoSEQ, a test for minimal residual disease (MRD) monitoring in lymphoid cancers Key Industry Insights - **Gross Margin Improvement**: - Q3 saw a 2% increase in gross margins from approximately 63% to 65% due to the X transition - Expected further improvement of 5% to 8% over the next 12 months post-launch [2][2][2] - **Operational Efficiency**: - Continued focus on operational expenditures (OpEx) with emphasis on EMR integration and reimbursement workflows - Anticipated leverage from business growth without significant additional investments [3][3][3] Growth Drivers - **EMR Integration**: - Ranked as the largest contributor to growth, enhancing volume and operational stickiness - Over 165 integrated sites as of Q3, with 40% of volume flowing through EMR integrated processes [4][8][9] - **Blood-Based Testing**: - Increasing adoption of blood-based MRD tests, allowing for more frequent testing compared to traditional bone marrow tests - Blood tests can be conducted every three months, while bone marrow tests are typically limited to once or twice a year [10][12][12] - **Community Penetration**: - Ongoing efforts to increase market penetration in community settings, with significant growth potential [5][5][5] - **Guideline Improvements**: - Positive changes in clinical guidelines supporting MRD testing across multiple indications, expected to drive further adoption [5][5][5] Reimbursement and Coverage - **Mantle Cell Lymphoma (MCL) Coverage**: - Secured coverage for recurrence monitoring, allowing for up to five tests post-treatment every six months, significantly increasing potential lifetime value per patient [17][18][18] - **ASP Increase**: - Average selling price (ASP) increased from $1,717 to $2,007, facilitating renegotiation with private payers for better rates [20][21][21] - **Future Coverage Opportunities**: - Potential to expand coverage models similar to MCL for other indications like Chronic Lymphocytic Leukemia (CLL) [22][23][23] Competitive Landscape - **Unique Testing Approach**: - Adaptive's approach leverages unique biology of lymphoid cancers, focusing on VDJ rearrangements for MRD assessment, distinguishing it from competitors [32][33][33] Future Catalysts - **Blood-Based Testing and Community Growth**: - Continued emphasis on blood-based testing and community growth as strategic priorities [34][34][34] - **Data Generation and Clinical Utility**: - Ongoing data generation and improvements in clinical guidelines expected to enhance the relevance of clonoSEQ [35][35][35] - **Clinical Trials**: - Significant clinical trials, such as MIDAS, demonstrating the ability to avoid transplants in MRD-negative patients, are pivotal for future growth [36][36][36] Conclusion - Adaptive Biotechnologies is positioned for growth through strategic improvements in gross margins, operational efficiencies, and expanding market penetration, particularly in blood-based testing and community settings. The company is also focused on enhancing reimbursement strategies and leveraging clinical data to solidify its market position.